Development of Drugs for Resistant Pathogens

3/1/02


Click here to start


Table of Contents

Development of Drugs for Resistant Pathogens

Development of Drugs for Resistant Pathogens

Development of Drugs for Resistant Pathogens Characteristics to Justify Development

Development of Drugs for Resistant Pathogens Preclinical IND Criteria

Development of Drugs for Resistant Pathogens Problems With IV Only Drugs

Antimicrobial Resistance in Nosocomial Pathogens

Drug Resistance in the USA Cubist SECURE surveillance study, 50 Centers

Penicillinase-Producing Staphylococcus aureus

Nosocomial Methicillin-Resistant Staphylococcus aureus (MRSA) Infections

Methicillin-Resistant Staphylococcus aureus: SFGH

MRSA in Bay Area Communities

Reports of Community-Acquired MRSA

Resistant Pathogens Nosocomial Enterococci Infections Resistant to Vancomycin*

Antibacterial Drugs in Development

Development of New Chemical Entity

Development of Drugs for Resistant Pathogens

Action Item 82

Action Item 82

Action Item 80

Development of Drugs for Resistant Pathogens Drug Categories

Development of Drugs for Resistant Pathogens Drug Categories

Vancomycin Use in the US

Development of Drugs for Resistant Pathogens Opinion

Development of Drugs for Resistant Pathogens Opinion

Development of Drugs for Resistant Pathogens Cubist Path with IV Only Narrow Spectrum Drug

Development of Drugs for Resistant Pathogens What is the answer? Frank Tally

Development of Drugs for Resistant Pathogens What is the answer? Frank Tally

Development of Drugs for Resistant Pathogens What is the answer? Frank Tally

Author: Francis P. Tally MD